StockData
PERRIGO Co plc logo

PERRIGO Co plc (PRGO) stock

PRGONYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 26, 2026Last filing: 10-Q on Nov 4, 2026Score 10/3030% below fair value
$16.55−0.28 (-1.66%)

Close on Nov 11, 2026Market cap $2.30BP/E –Yield 7.01%

PERRIGO Co plc saw revenue fall 4.5% to $4.09B over the twelve months to Sep 26, 2026. Operating income fell 677.9% to -$1.61B, moving the operating margin from 6.5% to -39.4%. Free cash flow was $168.20M, down 38.0% from a year earlier. At the latest close the market valued the company at $2.30B.

Revenue
$4.09B
-4.5% vs. a year earlier
Operating income
-$1.61B
-677.9% vs. a year earlier
Free cash flow
$168.20M
-38.0% vs. a year earlier
EPS, diluted
-$12.85
TTM Q3 2026

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 26, 2026

Valuation

Market cap
$2.30B
P/E ratio
–
Price to sales
0.56
Price to book
0.94
Dividend yield
7.01%
Free cash flow yield
7.32%

Fundamentals

Revenue
$4.09B
Net income
-$1.77B
EPS, diluted
-$12.85
Free cash flow
$168.20M
Book value per share
$17.51
Diluted shares
139M

Trading

Next earnings
Feb 25, 2027 (estimated, before the open)
Previous close
$16.83
Open
$16.58
Day's range
$16.38 – $16.72
Volume
1,295,827
Average volume (20 days)
2,391,027
Beta (5 years)
0.60
52-week range
$9.22 – $17.02
RSI (14 days)
61.1
Volatility (1 year)
50.5%
Relative volume
0.47×
WACC
6.4%

On 1 of our idea list: Most shorted (a warning list)

Market cap history

Month-end market cap since 2013, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.

PeriodPRGOS&P 500DifferencePRGO per yearS&P 500 per year
1 month+9.9%-2.4%+12.3 pts
3 months+31.4%-1.2%+32.6 pts
Year to date+27.3%+12.3%+15.0 pts
1 year+23.9%+12.4%+11.5 pts
3 years-32.3%+78.8%−111.1 pts-12.2%+21.4%
5 years-52.9%+75.2%−128.1 pts-14.0%+11.9%
10 years-75.5%+311.1%−386.6 pts-13.1%+15.2%

Twelve years at a glance

Fiscal years 2013 to 2025 and trailing twelve months, USD

Revenue

$4.09B-4.5% YoY

Gross profit

$1.32B-12.9% YoY

Operating income

-$1.61B-677.9% YoY

Net income

-$1.77B

EPS, diluted

-$12.85

Free cash flow

$168.20M-38.0% YoY
Reported periodTrailing twelve months

Press releases

Releases Perrigo filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Perrigo

Pharmaceutical Preparations

Perrigo Company plc provides over-the-counter self-care, health, and wellness products. The company operates through two business segments: Consumer Self-Care Americas and Consumer Self-Care International. Its product portfolio spans upper respiratory remedies, infant nutrition, digestive health, pain and sleep aids, oral hygiene, skincare, women's health, and dietary supplements. Perrigo produces retailer store brands as well as proprietary branded goods. Its customers include retail pharmacies, supermarkets, mass merchants, wholesalers, and e-commerce platforms, with Walmart serving as its largest individual customer.

Company profile, executives and history

Perrigo stock: common questions

What is Perrigo's stock price?

PRGO closed at $16.55 on Nov 11, 2026, down 1.66% on the day. Over the past 52 weeks it traded between $9.22 and $17.02.

What is Perrigo's market cap?

Perrigo was worth $2.30B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.

What is PRGO's P/E ratio?

Perrigo lost money over the twelve months to Sep 26, 2026 (diluted EPS -$12.85), so it has no meaningful P/E ratio.

How much revenue does Perrigo make?

Perrigo reported revenue of $4.09B for the twelve months to Sep 26, 2026, down 4.5% from a year earlier.

Does Perrigo pay a dividend?

Yes. Perrigo paid $1.16 per share over the last twelve months, a yield of 7.01% at the latest price, and has raised its annual dividend 11 years in a row.

When does Perrigo report earnings next?

Perrigo is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.

How has PRGO stock performed over the past year?

Including dividends, PRGO returned +23.9% over the past year, against +12.4% for the S&P 500.

How many PRGO shares are sold short?

25M shares were sold short at the latest FINRA report, 17.80% of the float, or 11.3 days of average trading volume.

Who are Perrigo's competitors?

Companies most similar to Perrigo by business, industry and size include PBH, AMRX, OGN, VTRS, ELAN.

See a number that looks wrong?